All In Biotech

Drug Trial Radar · NCT05753189

Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 362 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

362

Actual

Start

Feb 21, 2023

Primary completion

Feb 9, 2024

Study completion Feb 9, 2024

Sponsor

Lead sponsor
LENZ Therapeutics, IncAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Safety Study of the Long-Term Safety of LNZ100 \& LNZ101 in Presbyopic Subjects

Conditions

  • Presbyopia
  • Near Vision
  • Refractive Error
  • Eye Diseases

Interventions

  • Aceclidine+Brimonidine combination ophthalmic solutionDrug

    Aceclidine + Brimonidine combination ophthalmic solution

  • Aceclidine ophthalmic solutionDrug

    Aceclidine ophthalmic solution

  • VehicleDrug

    Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Treatment-Related TEAETime frame: 7 visits over a total duration of approximately 28 weeks

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Site #326

    Dothan, Alabama

  • Site #302

    Chandler, Arizona

  • Site #320

    Mesa, Arizona

  • Site #321

    Phoenix, Arizona

  • Site #328

    Phoenix, Arizona

  • Site #338

    Scottsdale, Arizona

  • Site #331

    Sun City, Arizona

  • Site #303

    Garden Grove, California

  • Site #313

    Glendale, California

  • Site #334

    La Jolla, California

  • Site #322

    Newport Beach, California

  • Site #306

    Petaluma, California

  • Site #337

    Rancho Cordova, California

  • Site #304

    Santa Barbara, California

  • Site #308

    Littleton, Colorado

  • Site #316

    Danbury, Connecticut

  • Site #319

    Crystal River, Florida

  • Site #309

    Mt. Dora, Florida

  • Site #339

    Morrow, Georgia

  • Site #340

    Northbrook, Illinois

  • Site #317

    Rock Island, Illinois

  • Site #301

    Overland Park, Kansas

  • Site #307

    Pittsburg, Kansas

  • Site #324

    Louisville, Kentucky

  • Site #336

    Alexandria, Minnesota

  • Site #330

    Kansas City, Missouri

  • Site #325

    St Louis, Missouri

  • Site #335

    Bozeman, Montana

  • Site #341

    Dover, New Jersey

  • Site #310

    Fargo, North Dakota

  • Site #332

    West Fargo, North Dakota

  • Site #329

    Cincinnati, Ohio

  • Site #323

    Powell, Ohio

  • Site #333

    Eugene, Oregon

  • Site #312

    Cranberry Township, Pennsylvania

  • Site #315

    Memphis, Tennessee

  • Site #311

    Smyrna, Tennessee

  • Site #314

    El Paso, Texas

  • Site #318

    San Antonio, Texas

  • Site #327

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.